Metabolic limitations of the use of nucleoside analogs in cancer therapy may be overcome by application of nanoparticles as drug carriers: A review

Drug Development Research

Volumn 71, Issue 7, 2010, Pages 383-394

  Hajdo, Lukasz ^a   Szulc, Aleksandra Beata ^a   Klajnert, Barbara ^a   Bryszewska, Maria ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

cytarabine; drug resistance; gemcitabine; nanoparticles; nucleoside analogs

Indexed keywords

ADENOSINE; ALBUMIN; AMPHOTERICIN B LIPID COMPLEX; ASPARAGINASE MACROGOL; CLADRIBINE; CLOFARABINE; CYTARABINE; CYTIDINE; DAUNORUBICIN; DENDRIMER; DOXORUBICIN; DRUG CARRIER; FLUDARABINE; FLUOROURACIL; GEMCITABINE; LIPOSOME; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; NANOPARTICLE; NANOSPHERE; NUCLEOSIDE ANALOG; PACLITAXEL; PEGINTERFERON ALPHA2A; POLYMER; PROPOFOL;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; HEPATITIS C; HIV RELATED KAPOSI SARCOMA; HUMAN; HYDROGEL; KAPOSI SARCOMA; LEUKEMIA; LYMPHOMATOUS MENINGITIS; MENINGITIS; METASTASIS; MYCOSIS; NEOPLASTIC MENINGITIS; NONHUMAN; OVARY CANCER; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SUSTAINED DRUG RELEASE;

EID: 78649661353     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20390     Document Type: Review

References (62)

1. Allen TM, Mehra T, Hansen C, Chin YC,. 1992. Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. Cancer Res 52: 2431-2439.
2. Angst MS, Drover DR,. 2006. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin Pharmacokinet 45: 1153-1176.
3. Appelhans D, Komber H, Quadir MA, Richter S, Schwarz S, van der Vlist J, Aigner A, Müller M, Loos K, Seidel J, Arndt KF, Haag R, Voit B,. 2009. Hyperbranched PEI with various oligosaccharide architectures: synthesis characterization ATP complexation and cellular uptake properties. Biomacromolecules 10: 1114-1124.
4. Bayne WF, Mayer LD, Swenson CE,. 2009. Pharmacokinet of CPX-351 (cytarabine/daunorubicin HCl) liposome injection in the mouse. J Pharm Sci 98: 2540-2548.
5. Biricova V, Laznickova A,. 2009. Dendrimers: analytical characterization and applications. Bioorg Chem 37: 185-192.
6. Diasio RB, Harris BE,. 1989. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16: 215-237.
7. Fanciullino R, Ciccolini J,. 2009. Liposome-encapsulated anticancer drugs: still waiting for the magic bullet? Curr Med Chem 16: 4361-4371.
8. Faraji AH, Wipf P,. 2009. Nanoparticles in cellular drug delivery. Bioorg Med Chem 17: 2950-2962.
9. Feldman E, Lancet J, Kolitz JE, Assianti E, Swenson C, Mayer L, Janoff A, Louie A,. 2007. Phase I study of a liposomal carrier (CPX-351) containing an optimized synergistic fixed molar ratio of cytarabine and daunorubicin in advanced leukemias and myelodysplastic syndromes. Am Soc Hematol Ann Meet Blood 110: 909.
10. Galmarini CM, Mackey JR, Dumontet C,. 2001. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15: 875-890.
11. Galmarini CM, Mackey JR, Dumontet Ch,. 2002. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3: 415-424.
12. Galmarini CM, Warren G, Kohli E, Zeman A, Mitin A, Vinogradov SV,. 2008. Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. Mol Cancer Ther 7: 3373-3380.
13. Gandhi V, Plunkett W,. 2002. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41: 93-103.
14. Gaumet M, Vargas A, Gurny R, Delie F,. 2008. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm 69: 1-9.
15. Gillies ER, Dy E, Frechet JMJ, Szoka FC,. 2005. Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. Mol Pharm 2: 129-138.
16. Giovannetti E, Laan AC, Vasile E, Tibaldi C, Nannizzi S, Ricciardi S, Falcone A, Danesi R, Peters GJ,. 2008. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples. Nucleosides Nucleotides Nucleic Acids 27: 720-725.
17. Gouy MH, Jordheim LP, Lefebvre I, Cros E, Dumontet Ch, Peyrottes S, Périgaud Ch,. 2009. Special feature of mixed phosphotriester derivatives of cytarabine. Bioorg Med Chem 17: 6340-6347.
18. Haley B, Frenkel E,. 2008. Nanoparticles for drug delivery in cancer treatment. Urol Oncol 26: 57-64.
19. Harris JM, Martin NE, Modi M,. 2001. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40: 539-551.
20. Hillaireau H, Le Doan T, Couvreur P,. 2006. Polymer-based nanoparticles for the delivery of nucleoside analogues. J Nanosci Nanotechnol 6: 2608-2617.
21. Jordheim LP, Dumontet C,. 2007. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta 1776: 138-159.
22. Kim I-Y, Kang Y-S, Lee DS, Park H-J, Choi E-K, Oh Y-K, Son H-J, Kim J-S,. 2009. Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J Control Release 140: 55-60.
23. Klajnert B, Bryszewska M,. 2001. Dendrimers: properties and applications. Acta Biochim Pol 48: 199-208.
24. Klajnert B, Appelhans D, Komber H, Morgner N, Schwarz S, Richter S, Brutschy B, Voit B,. 2008. The influence of densely organized maltose shells on the biological properties of poly(propylene imine) dendrimers: new effects dependent on hydrogen bonding. Chemistry 14: 7030-7041.
25. Kojima C, Regino C, Umeda Y, Kobayashi H, Kono K,. 2010. Influence of dendrimer generation and polyethylene glycol length on the biodistribution of PEGylated dendrimers. Int J Pharm 383: 293-296.
26. Kumar N, Hendriks BS, Janes KA, de Graaf D, Lauffenburger DA,. 2006. Applying computational modeling to drug discovery and development. Drug Discov Today 11: 806-811.
27. Lee BH, Lee YM, Sohn YS, Song SC,. 2002. A Thermosensitive Poly(organophosphazene). Gel Macromol 35: 3876-3879.
28. Lee CC, Gillies ER, Fox ME, Guillaudeu SJ, Fréchet JM, Dy EE, Szoka FC,. 2006. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc Natl Acad Sci USA 103: 16649-16654.
29. Lee SB, Song SC, Jin JI, Sohn YS,. 1999. A new class of biodegradable thermosensitive polymers. 2. Hydrolytic properties and salt effect on the lower critical solution temperature of poly(organophosphazenes) with methoxypoly(ethylene glycol) and amino acid esters as side groups. Macromolecules 32: 7820-7827.
30. Lee SM, Chun ChJ, Heo JY, Song SCh,. 2009. Injectable and thermosensitive poly(organophosphazene)hydrogels for a 5-fluorouracil delivery. J Appl Polymer Sci 113: 3831-3839.
31. Li F, Maag H, Alfredson T,. 2008. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. J Pharm Sci 97: 1109-1134.
32. Lu T, Sun J, Chen X, Zhang P, Jing X,. 2009. Folate-conjugated micelles and their folate-receptor-mediated endocytosis. Macromol Biosci 9: 1059-1068.
33. Mackey JR, Baldwin SA, Young JD, Cass CE,. 1998. Nucleoside transport and its significance for anticancer drug resistance. Drug Resist Updat 1: 310-324.
34. Malam Y, Loizidou M, Seifalian AM,. 2009. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 30: 592-599.
35. MÅnsson E, Flordal E, Liliemark J, Spasokoukotskaja T, Elford H, Lagercrantz S, Eriksson S, Albertioni F,. 2003. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol 65: 237-247.
36. Medina SH, El-Sayed MEH,. 2009. Dendrimers as carriers for delivery of chemotherapeutic agents. Chem Rev 109: 3141-3157.
37. Molina-Arcas M, Marcé S, Villamor N, Huber-Ruano I, Casado FJ, Bellosillo B, Montserrat E, Gil J, Colomer D, Pastor-Anglada M,. 2005. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 19: 64-68.
38. Mora-Huertas CE, Fessi H, Elaissari A,. 2009. Polymer-based nanocapsules for drug delivery. Int J Pharm 385: 113-142.
39. Myhren F, Borretzen B, Dalen A, Sandvold ML,. 2002. Gemcitabine derivatives. U.S. Patent US2,002,042,391.
40. Neerman MF, Chen HT, Parrish AR, Simanek EE,. 2004. Reduction of drug toxicity using dendrimers based on melamine. Mol Pharm 1: 390-393.
41. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C, CAELYX Breast Cancer Study Group,. 2004. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 15: 440-449.
42. Piedbois P,. 1998. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-Anal Group Cancer Clin Oncol 16: 301-308.
43. Port RE, Schuster C, Port CR, Bachert P,. 2006. Simultaneous sustained release of fludarabine monophosphate and Gd-DTPA from an interstitial liposome depot in rats: potential for indirect monitoring of drug release by magnetic resonance imaging. Cancer Chemother Pharmacol 58: 607-617.
44. Robak T,. 2005. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies. Transfus Apher Sci 32: 33-44. (Pubitemid 40292815)
45. Sarin H,. 2009. Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J Transl Med 7: 77.
46. Sarin H, Kanevsky AS, Wu H, Sousa AA, Wilson CM, Aronova MA, Griffiths GL, Leapman RD, Vo HQ,. 2009. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med 7: 51.
47. Sharma A, Sharma US,. 1997. Liposomes in drug delivery: progress and limitations. Int J Pharm 154: 123-140.
48. Stella B, Arpicco S, Rocco F, Marsaud V, Renoir JM, Cattel L, Couvreur P,. 2007. Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int J Pharm 344: 71-77.
49. Svenson S,. 2009. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 71: 445-462.
50. Takagaki K, Katsuma S, Kaminishi Y, Horio T, Nakagawa S, Tanaka T, Ohgi T, Yano J,. 2004. Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells. J Biochem 136: 733-740.
51. Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, Harvie P, Bermudes D, Mayer L,. 2009. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 33: 129-139.
52. Thomas TP, Majoros I, Kotlyar A, Mullen D, Holl MM, Baker JR,. 2009. Cationic poly(amidoamine) dendrimer induces lysosomal apoptotic pathway at therapeutically relevant concentrations. Biomacromolecules 10: 3207-3214.
53. Tomalia DA, Naylor AM, Goddard WA,. 1990. Starbust dendrimers: molecular-level control of size shape surface chemistry topology and flexibility from atoms to macroscopic matter. Angew Chem Int Ed 29: 138-175.
54. Viglianti BL,. 2009. Target molecular therapies: methods to enhance and monitor tumor drug delivery. Abdom Imag 34: 686-695.
55. Vinogradov SV, Zeman AD, Batrakova EV, Kabanov AV,. 2005. Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J Control Rel 107: 143-157.
56. Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR,. 1985. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 75: 632-642.
57. Wolinsky JB, Grinstaff MW,. 2008. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev 60: 1037-1055.
58. Yan Er, Barnes TJ, Fornasiero D, Clive A,. 2009. Prestidge the encapsulation and release of guanosine from PEGylated liposomes. J Liposome Res 19: 29-36.
59. Zhang J, Visser F, King KM, Baldwin SA, Young JD, Cass CE,. 2007. The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs. Cancer Metastasis Rev 26: 85-110.
60. Zhao X, Wu J, Muthusamy N, Byrd JC, Lee RJ,. 2007. Liposomal coencapsulated fludarabine and mitoxantrone for lymphoproliferative disorder treatment. J Pharm Sci 97: 1508-1518.
61. Zimm S, Collins JM, Miser J, Chatterji D, Poplack DG,. 1984. Cytosine arabinoside cerebrospinal fluid kinetics. Clin Pharmacol Ther 35: 826-830.
62. Zuber G, Dauty E, Nothisen M, Belguise P, Behr JP,. 2001. Towards synthetic viruses. Adv Drug Deliv Rev 52: 245-253.